Vertex hands its CF combo to the FDA; Tekmira soars on Ebola fervor;

@FierceBiotech: Novartis gears up for FDA scrutiny with a new blood cancer drug. Report | Follow @FierceBiotech

@JohnCFierce: Should Chris Viehbacher replace John Lechleiter at $LLY? Now that would be interesting. | Follow @JohnCFierce

@DamianFierce: The most metal researcher in all of science. More | Follow @DamianFierce

@EmilyMFierce: Science Cafés are growing in popularity. More | Follow @EmilyMFierce

> Teva ($TEVA) and partner Active Biotech have kicked off a Phase II trial to test the long-delayed laquinimod in patients with primary progressive multiple sclerosis. The drug is also under development for relapsing-remitting MS, progressive MS and Huntington's disease. News

> Vertex ($VRTX) has filed an FDA application for a combination of its cystic fibrosis treatments Kalydeco and lumacaftor, hoping to win an approval that would greatly expanded the number of CF patients eligible for its therapies. More

> Tekmira ($TKMR), one of the many biotechs developing treatments for Ebola, has watched its shares soar about 113% this year. Article

> Mathew Martoma, the SAC Capital Advisors trader convicted in biotech's largest insider-trading scandal, won't have to sit in prison while a federal court considers his motion for an appeal. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Spinoff Halyard Health gets boost from Ebola fears, stock up modestly in market debut. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Maryland provides seed financing to 15 med tech startups. Item | Follow @VarunSaxena2

@EmilyWFierce: This just in from the $ACT earnings call: "Actergan." | Follow @EmilyWFierce

> Former Boston Scientific engineer charged with intellectual theft. More

> Cantel Medical buys Italian healthcare manufacturer for $24.5M. News

Pharma News

@FiercePharma: ICYMI: PATH Malaria Vaccines Initiative nets $156 million from Gates Foundation. FierceVaccines story | Follow @FiercePharma

@EricPFierce: Boehringer Ingelheim unloads US API plant to Chinese company even as it expands in China. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Here's a first: Regeneron cuts forecast after hard-charging Eylea sales miss. Article | Follow @CarlyHFierce

> Actavis rides success of branded drugs and M&A to positive Q3. More

> Allergan loses fight to block Ackman from voting for a Valeant takeover. Article

Drug Delivery News

> Distinct, compartmental reactions in an 'artificial cell' offer controlled delivery action. More

> OptiNose submits NDA to FDA. Item

> MIT spinoff SQZ Biotech nabs startup prizes for cell-squeezing delivery enhancer. Story

> AstraZeneca, University of Manchester create new center for advanced drug delivery. Article

> Study: Timing of administration an oft-overlooked factor in drug delivery. More

Diagnostics News

> Diagnostics companies homing in on rapid mobile tests to quell Ebola outbreak. Report

> Myriad signs expanded deal with AbbVie for cancer Dx. More

> AstraZeneca shells out $150M for cancer Dx outfit Definiens. Item

> LabCorp bets $6B in diversification deal with Covance. Story

> Qiagen beats the Street's Q3 numbers with success of companion Dx and next-gen TB test. Article

Pharma Marketing News

> Who's king of the orphan drug hill? BMS, Merck, Celgene and Roche, to name a few. Article

> A tale of two studies: Prescribe Pradaxa 'with caution'? Or rely on FDA's safety backing? More

> Sovaldi's not the only superhero launch: Meet the rest of the pharma Avengers. Story

> Sales speedster Eylea faces a tougher track in new DME market, Regeneron SVP says. Article

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.